Bevacizumab biosimilar (Innovent Biologics)

贝伐珠单抗生物类似药（信达生物）

Report date: 2022/06/14 11:19:27

Base Information

Drug NameBevacizumab biosimilar (Innovent Biologics)
Drug Alias NameAnti-VEGF Monoclonal Antibody for Injection (Innovent Biologics)贝伐人源化单抗生物仿制药（信达生物）bevacizumab biosimilar（ Innovent Biologics）抗TNF-α单克隆抗体（信达生物）贝伐珠单抗生物仿制药（信达生物） +[14] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar
Mechanisms of ActionVascular endothelial growth factor A inhibitorsAngiogenesis inhibitors
TargetsVascular endothelial growth factor A
Therapy Area/IndicationsUterine Cervical NeoplasmsFallopian Tube NeoplasmsCarcinoma, Non-Small-Cell Lung +[10] 
Global Approved IndicationsCarcinoma, Non-Small-Cell LungColorectal Neoplasms
Approved Indications in ChinaCarcinoma, Non-Small-Cell LungColorectal Neoplasms
Original Approved Country/TerritoryMainland China
Original Approved Date2020/06/17
Country/TerritoryIndonesiaMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesInnovent Biologics(Suzhou) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesPT Etana Biotechnologies IndonesiaCoherus Biosciences IncInnovent Biologics(Suzhou) Co Ltd
Inactive CompaniesN/A
Active IndicationsUterine Cervical NeoplasmsFallopian Tube NeoplasmsCarcinoma, Non-Small-Cell Lung +[10] 
Inactive IndicationsN/A

Other Information

ATC CodeL01XC07
Related LinksN/A